Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Herpes zoster, Neuralgia
Clinical narrative: subdural pain; shingles on the left arm , shingles included their left upper back and shoulder their pectoral area of the chest and under the arm; This spontaneous case was reported by a consumer and describes the occurrence of NEURALGIA (subdural pain) and HERPES ZOSTER (shingles on the left arm , shingles included their left upper back and shoulder their pectoral area of the chest and under the arm) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027C21A and 033C21A) for COVID-19 vaccination. The patient's past medical history included Guillain-Barre syndrome. Concomitant products included LISINOPRIL, HYDROCODONE and IBUPROFEN for an unknown indication. On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In October 2021, the patient experienced HERPES ZOSTER (shingles on the left arm , shingles included their left upper back and shoulder their pectoral area of the chest and under the arm). On an unknown date, the patient experienced NEURALGIA (subdural pain). The patient was treated with VALACICLOVIR HYDROCHLORIDE (VALTREX) for Adverse event, at an unspecified dose and frequency. At the time of the report, NEURALGIA (subdural pain) had not resolved and HERPES ZOSTER (shingles on the left arm , shingles included their left upper back and shoulder their pectoral area of the chest and under the arm) was resolving. Patient stated that he is Guillen Barre survivor from 15 years ago, now at a 65% recovery, but considered permanently disable. Patient stated that vaccine was administered around Sep2021 but the card said otherwise. Patient stated he was not eligible to get the booster dose. Company comment: This case concerns a 65 year old with relevant medical of history of Guillain Barre Syndrome ( only 65 % recovered , permanent disabled) , who experienced  non- serious  unexpected events of Neuralgia and Herpes zoster which occurred  approximately  3- 4 months after vaccination with the 2nd dose of mRNA-1273 vaccine ( Moderna Covid 19 Vaccine )  . The patient was treated with Valacyclovir hydrocholoride. The re-challenge is not applicable since no additional doses will be administered and the events have not yet resolved. The age of the patient and the history of guillain barre syndrome with disability may be considered as a confounder for this case (since this state may have an effect on the immune reaction of the patient hence the developing herpes zoster ) . The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report; Sender's Comments: This case concerns a 65 year old with relevant medical of history of Guillain Barre Syndrome ( only 65 % recovered , permanent disabled) , who experienced  non- serious  unexpected events of Neuralgia and Herpes zoster which occurred  approximately  3- 4 months after vaccination with the 2nd dose of mRNA-1273 vaccine ( Moderna Covid 19 Vaccine )  . The patient was treated with Valacyclovir hydrocholoride. The re-challenge is not applicable since no additional doses will be administered and the events have not yet resolved. The age of the patient and the history of guillain barre syndrome with disability may be considered as a confounder for this case (since this state may have an effect on the immune reaction of the patient hence the developing herpes zoster ) . The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.